Source:http://linkedlifedata.com/resource/pubmed/id/18006808
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
22
|
pubmed:dateCreated |
2007-11-16
|
pubmed:abstractText |
Gene expression analysis has identified biologically relevant subclasses of breast cancer. However, most classification schemes do not robustly cluster all HER2+ breast cancers, in part due to limitations and bias of clustering techniques used. In this article, we propose an alternative approach that first separates the HER2+ tumors using a gene amplification signal for Her2/neu amplicon genes and then applies consensus ensemble clustering separately to the HER2+ and HER2- clusters to look for further substructure. We applied this procedure to a microarray data set of 286 early-stage breast cancers treated only with surgery and radiation and identified two basal and four luminal subtypes in the HER2- tumors, as well as two novel and robust HER2+ subtypes. HER2+ subtypes had median distant metastasis-free survival of 99 months [95% confidence interval (95% CI), 83-118 months] and 33 months (95% CI, 11-54 months), respectively, and recurrence rates of 11% and 58%, respectively. The low recurrence subtype had a strong relative overexpression of lymphocyte-associated genes and was also associated with a prominent lymphocytic infiltration on histologic analysis. These data suggest that early-stage HER2+ cancers associated with lymphocytic infiltration are a biologically distinct subtype with an improved natural history.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Nov
|
pubmed:issn |
1538-7445
|
pubmed:author |
pubmed-author:AlexeGabrielaG,
pubmed-author:BarnardNicolaN,
pubmed-author:BhanotGyanG,
pubmed-author:DalginGul SGS,
pubmed-author:DeLisiCharlesC,
pubmed-author:GanesanShridarS,
pubmed-author:HarrisLyndsayL,
pubmed-author:LevineArnold JAJ,
pubmed-author:MartelMaritzaM,
pubmed-author:MesirovJill PJP,
pubmed-author:ScanfeldDanielD,
pubmed-author:TamayoPabloP
|
pubmed:issnType |
Electronic
|
pubmed:day |
15
|
pubmed:volume |
67
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
10669-76
|
pubmed:dateRevised |
2009-11-19
|
pubmed:meshHeading |
pubmed-meshheading:18006808-Breast Neoplasms,
pubmed-meshheading:18006808-Cell Proliferation,
pubmed-meshheading:18006808-Cluster Analysis,
pubmed-meshheading:18006808-Computational Biology,
pubmed-meshheading:18006808-Databases, Genetic,
pubmed-meshheading:18006808-Gene Expression Profiling,
pubmed-meshheading:18006808-Gene Expression Regulation, Neoplastic,
pubmed-meshheading:18006808-Humans,
pubmed-meshheading:18006808-Lymphocytes,
pubmed-meshheading:18006808-Multigene Family,
pubmed-meshheading:18006808-Neoplasm Invasiveness,
pubmed-meshheading:18006808-Principal Component Analysis,
pubmed-meshheading:18006808-RNA, Messenger,
pubmed-meshheading:18006808-Receptor, erbB-2,
pubmed-meshheading:18006808-Recurrence
|
pubmed:year |
2007
|
pubmed:articleTitle |
High expression of lymphocyte-associated genes in node-negative HER2+ breast cancers correlates with lower recurrence rates.
|
pubmed:affiliation |
The Broad Institute of the Massachusetts Institute of Technology and Harvard, Cambridge, Massachusetts, USA.
|
pubmed:publicationType |
Journal Article,
Research Support, U.S. Gov't, Non-P.H.S.,
Research Support, Non-U.S. Gov't,
Research Support, N.I.H., Extramural
|